Scientists have successfully used an inhaled RNA medicine to reduce the activity of a selected gene target inside human lungs, providing early evidence that gene-silencing medicines may be delivered directly to the respiratory system.
The experimental treatment, called ARO-RAGE, was evaluated in a first-in-human phase 1/2a clinical trial published in Nature Medicine.
The study included 58 healthy volunteers and 19 people with asthma.
The treatment produced a strong and sustained reduction in biological markers linked to its intended target while relatively little of the medicine entered the bloodstream.
That combination suggests that the inhaled treatment was acting mainly inside the lungs.
What is an RNA-silencing medicine?
Genes contain instructions that cells use to produce proteins.
Between the DNA instructions and the final protein is a messenger molecule called RNA.
Some medicines can be designed to interfere with a particular RNA message.
This can reduce the amount of a selected protein that the cell produces.
The technique is known as RNA interference, or RNAi.
Several RNA-interference medicines are already used clinically, particularly for targets involving the liver.
Delivering these medicines effectively to other organs, including the lungs, has been more difficult.
What does ARO-RAGE target?
ARO-RAGE is designed to reduce production of a protein called RAGE, short for receptor for advanced glycation end products.
RAGE participates in inflammatory signalling and has been implicated in several lung diseases.
Researchers are therefore investigating whether reducing RAGE activity could eventually help conditions involving abnormal airway or lung inflammation.
The new study, however, was primarily designed to establish whether the inhaled medicine could safely reach its target and reduce RAGE-related biological signals in humans.
What did the researchers find?
Participants inhaled different doses of ARO-RAGE.
Researchers found a dose-related and sustained reduction in biological markers associated with the RAGE pathway.
Only low levels of the drug were found in the bloodstream.
This is important because it suggests that inhaled RNA interference can potentially deliver a gene-silencing effect directly to lung tissue while limiting exposure elsewhere in the body.
Did it improve asthma?
This study does not establish that ARO-RAGE is an effective asthma treatment.
Only 19 people with asthma participated, and the trial was not designed or large enough to show whether the treatment prevents asthma attacks, improves breathing in everyday life or reduces the need for other asthma medicines.
The main achievement was demonstrating biological target engagement — evidence that the treatment reached the intended pathway and successfully reduced it.
Why could this be important?
If researchers can reliably switch down selected disease-related genes inside the lungs, the technology could potentially create an entirely new class of respiratory medicines.
Instead of repeatedly blocking a protein after it has already been produced, RNA-interference treatment attempts to reduce its production closer to the source.
The principle might eventually have applications beyond one disease.
But whether that possibility translates into useful treatments remains unknown.
What are the important limitations?
This was an early phase 1/2a study.
Most participants were healthy volunteers, and only a small number had asthma.
The study demonstrates safety over the period examined and strong biological activity, but it does not yet demonstrate meaningful improvement in patient health.
Larger and longer clinical trials will be necessary.
The study was also sponsored by the developer of ARO-RAGE, and several authors had relationships with the company.
That does not invalidate the findings, but independent confirmation and larger clinical studies are important.
Evidence so far
First-in-human proof that inhaled RNA interference can strongly suppress its intended lung target — clinical benefit has not yet been established
This is an important technology-development result rather than proof of a new asthma or COPD treatment.
Future trials must establish whether suppressing this pathway actually improves symptoms, prevents attacks or changes the course of lung disease.
